November MIMS Update
Some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products Dapagliflozin (propanediol monohydrate) and sitagliptin (phosphate monohydrate) (Sidapvia) is a combination of the …
UTIs in the NT
PDL has some advice for pharmacists practising in the Northern Territory Recent legislative change now allows Northern Territory pharmacists to provide antibiotic treatment without a prescription from a prescriber for …
Mandatory reporting: a pharmacist’s responsibilities
Andrew Tooms takes look around the nation at the legislative and regulatory responsibilities of pharmacists when confronted by possible abuse of a minor Author: Andrew Tooms BSc (Hons), LLB, MHM, AACPA, …
Relief from constipation: effective strategies and relief
As many as 20% of Australian adults experience constipation,1 and about 50% of pharmacists recommend treatments for this condition on a daily basis.2. Constipation is often associated with factors such …
Your Offshore Refresher is closer than ever!
Join us for the 49th PSA Offshore Refresher Conference to be held in Vietnam at Hoi An and Ho Chi Min City from 14 – 22 May 2025. Closer than ever, with …
Raising awareness of RSV vaccine options, midazolam and Wegovy strengths
PDL has some advice on RSV vaccination, and the strengths of midazolam and Wegovy This Practice Alert highlights some recent practice issues reported to PDL Professional Officers. Respiratory Syncytial Virus …
Is your pharmacy prepared for the new paracetamol pack sizes and accessibility changes?
The Therapeutic Goods Administration (TGA) decision on paracetamol scheduling has resulted in changes to the packaging and sale of certain oral, non-prescription paracetamol products, effective 1st February 2025. This change affects …
Have you received an Aphra notification?
During your healthcare career, you may receive a regulatory notification Regulatory notifications are a mechanism for the public to raise any concerns about their healthcare experience and are an integral …
October MIMS Update
A look at some of the recent changes to the medicines landscape, with new products, presentations, indications and contraindications New Products Selpercatinib (Retevmo) is an orally available, small molecule inhibitor …
Schedule 3 supply of therapeutic vaping products
From 1 October 2024, therapeutic vapes with a nicotine concentration of 20mg/mL or less will be available in pharmacies to patients 18 years or over without a prescription. Date of …
Never again: multi-practitioner perspectives of key medication safety learnings from coroner’s cases
Incidents described in coroner’s reports are an in-depth and factual account of events leading to a tragic outcome and provide an opportunity for clinicians to learn critical lessons These reports …
NSW Pharmaceutical Services Unit e-cigarette Compliance Program
PDL has some advice for pharmacists on lawfully supplying vapes for smoking cessation Pharmacists would be aware of the down scheduling of some nicotine vaping or e-cigarette products to S3 …